DK166564B1 - Temazepam composition, and process for producing it - Google Patents
Temazepam composition, and process for producing it Download PDFInfo
- Publication number
- DK166564B1 DK166564B1 DK69287A DK69287A DK166564B1 DK 166564 B1 DK166564 B1 DK 166564B1 DK 69287 A DK69287 A DK 69287A DK 69287 A DK69287 A DK 69287A DK 166564 B1 DK166564 B1 DK 166564B1
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- approx
- temazepam
- solution
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 31
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 title claims description 27
- 229960003188 temazepam Drugs 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000014766 Mentha X piperi var citrata Nutrition 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 235000008660 Mentha x piperita subsp citrata Nutrition 0.000 description 1
- 240000003637 Monarda citriodora Species 0.000 description 1
- 235000002431 Monarda citriodora Nutrition 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- WPNMLCMTDCANOZ-UHFFFAOYSA-N [5-chloro-2-(methylamino)phenyl]-phenylmethanone Chemical compound CNC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 WPNMLCMTDCANOZ-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
i DK 166564 B1in DK 166564 B1
Opfindelsen angår en temazepam-(3-hydroxydiazepam)~komposition og en fremgangsmåde til fremstilling af samme.The invention relates to a temazepam (3-hydroxydiazepam) composition and a process for preparing the same.
Opfindelsen angår navnlig et væskeformigt temazepampræparat, der er egnet til oral indgivelse. Der kendes allerede kapsler, som 5 indeholder temazepam, til oral indgivelse, og formålet med at udvikle et væskeformigt præparat af medikamentet er at fremme hurtigere absorption og således hurtigere søvnfremkaldelse såvel som at give udøvere og patienter et brugbart valg.In particular, the invention relates to a liquid temazepam composition suitable for oral administration. Capsules containing temazepam are already known for oral administration, and the purpose of developing a liquid formulation of the drug is to promote faster absorption and thus faster sleep induction as well as to give practitioners and patients a useful choice.
Temazepam er kun svagt opløseligt i vand og er ustabil i vandig 10 opløsning. Ved henstand har temazepam i sig selv og dets sønder del ingsprodukter således en tendens til at udfældes fra den vandige opløsning. På den anden side er ikke-vandige opløsningsmidler almindeligvis uacceptable til human indtagelse.Temazepam is only slightly soluble in water and is unstable in aqueous solution. Thus, upon standing, temazepam itself and its disintegrating products tend to precipitate from the aqueous solution. On the other hand, non-aqueous solvents are generally unacceptable for human consumption.
Det er et formål med opfindelsen at tilvejebringe et væskefor-15 migt temazepampræparat, der er egnet til oral indgivelse og er velsmagende samtidig med, at den besidder en acceptabel opbevaringsstabilitet og viscositet.It is an object of the invention to provide a liquid temazepam preparation which is suitable for oral administration and is palatable while possessing an acceptable storage stability and viscosity.
Der tilvejebringes følgelig ifølge opfindelsen en temazepam-komposition, der ikke omfatter mere end ca. 0,2% vægt/volumen 20 temazepam, ikke mere end ca. 15% vægt/volumen af mindst en polymer alkohol, ikke mindre end ca. 8% vægt/volumen af en lavtkogende alkohol, fortrinsvis en monovalent alkohol, såsom ethanol eller iso-propanol, fortrinsvis ethanol, ikke mindre end ca. 40% vægt/ volumen glycerol, ikke mere end ca. 45% af en vandig opløsning af mindst en 25 hexavalent alkohol, et sol ubi li seringsmiddel, mindst et smagsstof og mindst én puffer til opretholdelse af kompositionens pH på mellem 7,3 og 8,3 samt en fremgangsmåde til fremstilling af kompositionen.Accordingly, according to the invention, a temazepam composition is provided which comprises no more than ca. 0.2% w / v 20 temazepam, not more than approx. 15% w / v of at least one polymeric alcohol, not less than approx. 8% w / v of a low boiling alcohol, preferably a monovalent alcohol such as ethanol or iso-propanol, preferably ethanol, not less than about 10%. 40% w / v glycerol, not more than approx. 45% of an aqueous solution of at least one hexavalent alcohol, one solubilizing agent, at least one flavor and at least one buffer to maintain the pH of the composition between 7.3 and 8.3 and a process for preparing the composition.
Temazepamkoncentrationen er fortrinsvis ca. 0,2%, idet dette svarer til en koncentration på 10 mg/5 ml, dvs. én normal dosis pr.The temazepam concentration is preferably ca. 0.2%, which corresponds to a concentration of 10 mg / 5 ml, ie. one normal dose per day.
30 teskefuld.30 teaspoons.
Sol ubi li seringsmidl et anvendes for at stabilisere, dispergere og danne kompleks med temazepam og smagsbestanddel en(-delene) (der almindeligvis er uopløselig i vand) og omfatter fortrinsvis polyvi-nylpyrrolidon (Povidon), som udgør op til mindst ca. 2% vægt/volumen 35 af kompositionen.The solubilizing agent is used to stabilize, disperse, and complex with temazepam and flavor constituent one (s) (which are generally insoluble in water) and preferably comprise polyvinylpyrrolidone (Povidone) which is up to at least approx. 2% w / v of the composition.
Kompositionen omfatter et opløsningsmiddel system, som almindeligvis udgøres af vandfri ethanol, glycerol, en polyethylenglycol og en hexavalent alkohol, såsom mannitol eller sorbitol. Der kræves ethanol som opløsningsmiddel til temazepam for at holde DK 166564 B1 2 kompositionens viskositet på et acceptabelt lavt niveau under fremstilling og anvendelse og som konserveringsmiddel til hæmning af mikrobiel vækst. Ethanol mængden bør fortrinsvis ikke overstige ca.The composition comprises a solvent system which is generally composed of anhydrous ethanol, glycerol, a polyethylene glycol and a hexavalent alcohol such as mannitol or sorbitol. Ethanol as solvent for temazepam is required to maintain the viscosity of the composition at an acceptable low level during preparation and use and as a preservative for inhibiting microbial growth. The ethanol amount should preferably not exceed about
10%.10%.
5 Polyethylenglycolen kan være polyethylenglycol 100, men er fortrinsvis polyethylenglycol 400. Den hexavalente alkohol er fortrinsvis sorbitol, som er mere lettilgængelig og har en bedre opløselighed i vand end mannitol. Glycerolmængden er fortrinsvis mindst ca. 50% vægt/volumen; denne mængde bør ikke øges for meget, 10 idet dette vil øge kompositionens osmotiske tryk og føre til en "brændende" smag, medens nedsættelse af glycerol indholdet til under ca. 40% vil reducere dets virkning som et konserveringsmiddel.The polyethylene glycol may be polyethylene glycol 100, but is preferably polyethylene glycol 400. The hexavalent alcohol is preferably sorbitol, which is more readily available and has a better solubility in water than mannitol. The amount of glycerol is preferably at least approx. 50% w / v; this amount should not be increased too much, 10 as this will increase the osmotic pressure of the composition and lead to a "burning" taste, while reducing the glycerol content to below approx. 40% will reduce its effect as a preservative.
.Temazepam er følsom over for pH, og dets sønderdeling kan også ændre kompositionens pH med tiden. Der kræves derfor en puffer, og 15 det initielle pH er fortrinsvis ca. 7,8. Egnede puffere indbefatter di natriumhydrogenphosphat (natriumphosphat BP, vandfrit) og citron-syremonohydrat (den tilstedeværende vandmængde i den anvendte lille citronsyremængde er ubetydelig).Temazepam is sensitive to pH and its decomposition can also change the pH of the composition over time. Therefore, a buffer is required and the initial pH is preferably approx. 7.8. Suitable buffers include di sodium hydrogen phosphate (sodium phosphate BP, anhydrous) and citric acid monohydrate (the amount of water present in the small amount of citric acid used is negligible).
Smagsstoffet(-stofferne) kan omfatte pebermynteolie BP og/eller 20 citronolie. Citronolien er fortrinsvis fri for terpener for at forbedre dets vandbiandbarhed.The flavoring agent (s) may comprise peppermint oil BP and / or lemon oil. The lemon oil is preferably free of terpenes to improve its water compatibility.
Kompositionen omfatter almindeligvis yderligere et farvestof, såsom chlorophyl, for at forbedre det æstetiske udseende.The composition generally further comprises a dye, such as chlorophyll, to enhance the aesthetic appearance.
Den rækkefølge, hvori kompositionens bestanddele blandes, er 25 uvæsentlig. Fremgangsmåden omfatter fortrinsvis, at den vandige opløsning og mindst noget af pufferen (pufferne) kombineres til opnåelse af en første opløsning A, af mindst nogle af al kohol bestanddelene, sol ubil i seringsmidlet og temazepam kombineres til opnåelse af en anden opløsning B, at opløsningerne A og B kombine-30 res, og at smagsstoffet(-stofferne) tilsættes.The order in which the constituents of the composition are mixed is insignificant. Preferably, the process comprises combining the aqueous solution and at least some of the buffer (s) to obtain a first solution A, of at least some of all the alcohol components, soluble in the lubricant, and temazepam to obtain a second solution B A and B are combined and the flavor (s) added.
Opfindelsen vil nu blive beskrevet i form af et eksempel.The invention will now be described by way of example.
EksempelExample
Der fremstilles en komposition i overensstemmelse med opfin-35 del sen ud fra de bestanddele, som er anført i nedenstående tabel.A composition according to the invention is prepared from the constituents listed in the table below.
5 DK 166564 B1 35 DK 166564 B1 3
Tabel % vægt/vol urnen mg/5 ml (g/100ml)Table% w / v urn mg / 5 ml (g / 100ml)
Temazepam 0,206 10Temazepam 0.206 10
Povidon (Kollidon 25) BP 2,000 100Povidon (Kollidon 25) BP 2,000 100
Polyethylenglycol 400 BP 5,000 250Polyethylene glycol 400 BP 5,000 250
Ethanol, absolut (vandfrit) BP 8,800 440 10 Glycerol BP 50,000 2500Ethanol, absolute (anhydrous) BP 8,800 440 10 Glycerol BP 50,000 2500
Natriumphosphat (vandfrit) BP 2,500 125Sodium Phosphate (Anhydrous) BP 2,500 125
Citronsyre 0,125 6,25Citric Acid 0.125 6.25
ChlorophyT 'JJ' 0,012 0,60ChlorophyT 'JJ' 0.012 0.60
Sorbitolopløsning (70%) BP 45,000 2250 15 Pebermynteolie BP 0,035 1,75Sorbitol Solution (70%) BP 45,000 2250 Peppermint Oil BP 0.035 1.75
Citronsmag Supara SL 2300 0,060 3Lemon flavor Supara SL 2300 0.060 3
Glycerol BP Op til 100.000 volumer/5 ml *Glycerol BP Up to 100,000 volumes / 5 ml *
Der inkluderes et overskud på 3%. Beslutningen om at inkludere 20 dette er baseret på analyseresultater fra partier fremstillet ved pilotforsøg, hvor der forekom tab på mellem 2 og 7%. Det menes, at tabene skyldes den høje viscositet af temazepamopløsningen, som tilsættes glycerolen.A surplus of 3% is included. The decision to include this is based on analysis results from batches produced by pilot trials where losses of between 2 and 7% occurred. It is believed that the losses are due to the high viscosity of the temazepam solution added to the glycerol.
25 Sorbitol sirup udhældes i en beholder af rustfrit stål og opvarmes til 60°C. Der tilsættes vandfrit natriumphosphat, og der blandes med et blandeapparat med høj forskydning indtil opløsning. Blandingen får lov til at afkøle til ca. 40°C, og der tilsættes citronsyre og blandes med et blandeapparat med høj forskydning, 30 indtil det er opløst. Der tilsættes Chlorophyll JJ, og der blandes med et bl andeapparat med høj forskydning, indtil der opnås en ensartet grøn opløsning. Blandingen får lov til at afkøle til stuetemperatur (dvs. ca. 20°C) i løbet af ca. 24 timer til opnåelse af opløsning A.25 Sorbitol syrup is poured into a stainless steel container and heated to 60 ° C. Anhydrous sodium phosphate is added and mixed with a high shear mixer until dissolved. The mixture is allowed to cool to ca. 40 ° C and citric acid is added and mixed with a high shear mixer until dissolved. Chlorophyll JJ is added and mixed with a high shear blender until a uniform green solution is obtained. The mixture is allowed to cool to room temperature (i.e., about 20 ° C) over approx. 24 hours to obtain solution A.
35 I en anden beholder af rustfrit stål afvejes glycerolen, og polyethylenglycol 400 og 90% af ethanol en tilsættes og blandes med et blandeapparat med høj forskydning. Under fortsat blanding blev povidon langsomt tilsat, og der blev blandet indtil det var opløst.In another stainless steel container, the glycerol is weighed and polyethylene glycol 400 and 90% of ethanol are added and mixed with a high shear mixer. With continued mixing, povidone was slowly added and mixed until dissolved.
Der blev tilsat temazepam, og der blev blandet, indtil det var DK 166564 B1 4 opløst, til opnåelse af opløsning B.Temazepam was added and mixed until dissolved to obtain solution B.
Den afkølede opløsning A blev langsomt sat til opløsning B ved blanding med en rørerarm. Der blev derpå tilsat og iblandet pebermynte- og citronsmagsstoffer. Beholderne til smagsstoffet blev 5 skyllet med resten af ethanol en, og skylleopløsningerne blev sat til præparationen og blandet. Præparationen blev tilsat glycerol op til volumen og blandet, og pH blev justeret til mellem 7,6 og 8,0 under anvendelse af citronsyre eller koncentreret natriumhydroxidopiøsing.The cooled solution A was slowly added to solution B by mixing with a stirring arm. Peppermint and lemon flavors were then added and mixed. The flavors containers were rinsed with the remainder of ethanol one and the rinsing solutions were added to the preparation and mixed. The preparation was added glycerol up to volume and mixed and the pH was adjusted to between 7.6 and 8.0 using citric acid or concentrated sodium hydroxide solution.
Det opnåede produkt var en klar, lys, viskøs, grøn væske med en 10 lugt og smag af citron og pebermynte. pH var på fra 7,3 til 8,3 ved 20°C, og vægten pr. ml var fra 1,20 til 1,26 g ved 20°C. Absorpti-onsspektrummet viste tilstedeværelse af temazepam og chlorophyl, og HPLC viste tilstedeværelse af fra 1,96 til 2,2 mg/ml (fra 98 til 110%) temazepam. HPLC og spectrophotofluorometrisk analyse viste 15 tilstedeværelse af ikke mere end 2,5% organiske urenheder, herunder ikke mere end 0,5% 2-methylamino-5-chlorbenzophenon og fluorescerende nedbrydningsprodukter under ét. GLC viste, at ethanol indholdet var fra 7,4 til 9% vægt/volumen.The product obtained was a clear, light, viscous, green liquid with a 10 odor and taste of lemon and peppermint. The pH was from 7.3 to 8.3 at 20 ° C, and the weight per ml was from 1.20 to 1.26 g at 20 ° C. The absorption spectrum showed the presence of temazepam and chlorophyll, and HPLC showed the presence of 1.96 to 2.2 mg / ml (from 98 to 110%) of temazepam. HPLC and spectrophotofluorometric analysis showed the presence of no more than 2.5% organic impurities, including no more than 0.5% 2-methylamino-5-chlorobenzophenone and fluorescent degradation products together. The GLC showed that the ethanol content was from 7.4 to 9% w / v.
Ved henstand forblev produktets specifikation som anført oven 20 for med undtagelse af, at temazepamindholdet faldt til ikke under 1,8 mg/ml (90%), og andelen af organiske urenheder steg til ikke over 5%, herunder ikke mere end 2,5% 2-methylamino-5-chlorbenzophe-non og ikke mere end 1,5% fluorescerende nedbrydningsprodukter. Produktet forblev inden for disse (acceptable) grænser i ikke under t\ 25 år.On standing, the product specification remained above 20 except that the temazepam content dropped to not less than 1.8 mg / ml (90%) and the proportion of organic impurities increased to no more than 5%, including not more than 2.5 % 2-methylamino-5-chlorobenzopheone and no more than 1.5% fluorescent degradation products. The product remained within these (acceptable) limits for not less than 25 years.
Produktet viste sig ydermere at besidde en acceptabel smag og at fremme hurtig absorption, idet de terapeutiske plasmaniveauer af temazepam blev nået ca. 15 min efter indgivelse i sammenligning med de tidligere opnåede 30 min med kapsler.Furthermore, the product was found to possess an acceptable taste and to promote rapid absorption, with the therapeutic plasma levels of temazepam being reached approx. 15 min after administration compared to the previously obtained 30 min with capsules.
30 3530 35
Claims (14)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK69287A DK166564B1 (en) | 1987-02-11 | 1987-02-11 | Temazepam composition, and process for producing it |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK69287 | 1987-02-11 | ||
| DK69287A DK166564B1 (en) | 1987-02-11 | 1987-02-11 | Temazepam composition, and process for producing it |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK69287D0 DK69287D0 (en) | 1987-02-11 |
| DK69287A DK69287A (en) | 1988-08-12 |
| DK166564B1 true DK166564B1 (en) | 1993-06-14 |
Family
ID=8096448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK69287A DK166564B1 (en) | 1987-02-11 | 1987-02-11 | Temazepam composition, and process for producing it |
Country Status (1)
| Country | Link |
|---|---|
| DK (1) | DK166564B1 (en) |
-
1987
- 1987-02-11 DK DK69287A patent/DK166564B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK69287A (en) | 1988-08-12 |
| DK69287D0 (en) | 1987-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0524587B1 (en) | Therapeutic compositions for intranasal administration which include ketorolac TM | |
| EP2890401B1 (en) | Gelling formulation containing ketamine | |
| CA2090422C (en) | Pharmaceutical composition of florfenicol | |
| NO166835B (en) | PROCEDURE FOR THE PREPARATION OF AN Aqueous SOLUTION CONTAINING LIPID SOLUBLE VITAMIN AND / OR UBIKINON | |
| RS54524B1 (en) | PROCEDURE FOR PREPARING LEVOTHYROXINE SOLUTION | |
| Ceschel et al. | In vitro permeation through porcine buccal mucosa of caffeic acid phenetyl ester (CAPE) from a topical mucoadhesive gel containing propolis | |
| NO165277B (en) | PROCEDURE FOR PREPARING A STABLE, Aqueous, SID SOLUTION OF CIS PLATINUM. | |
| DK166564B1 (en) | Temazepam composition, and process for producing it | |
| GB2185887A (en) | Temazepam composition | |
| JPH0717498B2 (en) | Antitussive expectorant soft capsule | |
| JPH11246513A (en) | Azulene aqueous solution | |
| CN113143992A (en) | Skin antibacterial cream and preparation method thereof | |
| CN106176769B (en) | Long-acting veterinary Ursocycline injection and preparation method thereof | |
| CN111773198A (en) | Novel soft capsule of eldecalcitol and preparation method thereof | |
| NO322334B1 (en) | Lyophilized preparation of human bone morphogenetic factor MP52, and method of preparing a lyophilized preparation of human bone morphogenetic factor MP52 | |
| NO330296B1 (en) | Solution of N- [O- (p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and medical product | |
| JPH03109326A (en) | Fleroxacin eye drop | |
| KR100344198B1 (en) | Composition of sildenafil citrate dosage form | |
| KR20020094052A (en) | Aqueous liquid preparation | |
| RU2129395C1 (en) | Alcohol-free drink "vitaminny" | |
| JPH0157091B2 (en) | ||
| Van Harken et al. | Comparative absorption following the administration of a drug to rats by oral gavage and incorporation in the diet | |
| JPH07116039B2 (en) | Stable Trimethoquinol Hydrochloride Internal Solution | |
| RU2832908C1 (en) | Oral dosage form of 3,3'-diindolylmethane in form of chewing marmalade | |
| KR100425900B1 (en) | Immediate-release soft capsule containing a highly concentrated and transparent solution of ibuprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |